Google (GOOGL): Taking Stock of Its Valuation Following Recent Share Price Momentum

Alphabet (GOOGL) made headlines this week with a price move that has piqued the interest of investors and onlookers alike. While there is no single event or announcement driving the action, the uptick in Alphabet’s share price has people wondering if it signals a shift in the company’s outlook or is simply a case of broader market enthusiasm.

Looking at the bigger picture, Alphabet’s stock has shown strong momentum this year, gaining 58% over the past year with an impressive 32% jump in the past 3 months. This builds on solid trends, supported by double-digit annual revenue and net income growth, and follows a stream of steady performances rather than a surprise news event. The story has become less about headline-making updates and more about Alphabet’s ability to execute and expand in a competitive tech landscape.

This recent surge raises the big question for investors: are shares still undervalued after such gains, or has the market already priced in the company’s future growth potential?

Advertisement

Most Popular Narrative: 1% Undervalued

According to the most popular narrative, Alphabet’s shares are trading just below their estimated fair value, suggesting the company remains attractively priced despite recent gains.

"Alphabet Inc. combines market dominance, innovation, and financial strength, making it one of the most compelling investment opportunities in the tech sector. As the cheapest stock among the Magnificent 7, it offers a unique blend of value and growth potential."

Curious what makes Alphabet’s fair value stand out? There is a bold set of projections at work, including stellar profit margins and a playbook for continued growth. The financial engine behind this estimate might surprise those tracking big tech’s next moves. Want to see what underpins the narrative’s confidence? Dive in for the surprising figures and the big assumptions fueling this valuation.

Result: Fair Value of $237.43 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, regulatory challenges or shifts in digital ad spending could quickly change Alphabet’s outlook and reshape the current valuation narrative.

Find out about the key risks to this Alphabet narrative.

Another View: Market Multiples Tell a Different Story

While some models suggest Alphabet is undervalued, a look at typical market valuation ratios paints a tougher picture. Compared to similar companies in its industry, Alphabet actually appears somewhat expensive. Could the market's optimism be outpacing fundamentals?

See what the numbers say about this price — find out in our valuation breakdown.
NasdaqGS:GOOGL PE Ratio as at Sep 2025
NasdaqGS:GOOGL PE Ratio as at Sep 2025
Stay updated when valuation signals shift by adding Alphabet to your watchlist or portfolio. Alternatively, explore our screener to discover other companies that fit your criteria.

Build Your Own Alphabet Narrative

If you see things differently or want to dig deeper into the numbers, you can craft your own personalized take in just a few minutes. Do it your way.

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Alphabet.

Looking for More Smart Investment Ideas?

Break away from the crowd and get ahead with unique stock ideas tailored to where the market is headed. These tailored tools could inspire your next move and help you avoid missing significant growth opportunities.

  • Strengthen your portfolio by tracking companies earning solid payouts and benefiting from dividend stocks with yields > 3%. This approach can help create consistent income streams for the long term.
  • Explore future-focused opportunities by targeting breakthroughs with quantum computing stocks and access pioneers leading advancements in quantum innovations.
  • Find potential bargains before the market notices them by using undervalued stocks based on cash flows to identify stocks that may be well positioned for growth based on real cash flow fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Kshitija Bhandaru

Kshitija Bhandaru

Kshitija (or Keisha) Bhandaru is an Equity Analyst at Simply Wall St and has over 6 years of experience in the finance industry and describes herself as a lifelong learner driven by her intellectual curiosity. She previously worked with Market Realist for 5 years as an Equity Analyst.

About NasdaqGS:GOOGL

Alphabet

Offers various products and platforms in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Canada, and Latin America.

Undervalued with solid track record.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
47 users have followed this narrative
2 users have commented on this narrative
7 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
67 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
23 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
24 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.8% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BL
Blagget
TERA logo
Blagget on Terra Balcanica Resources ·

The C$4M Explorer Positioned to Become Europe's First Antimony Mine

Fair Value:CA$0.487.5% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
CHTR logo
david_6nroa on Charter Communications ·

Charter is undervalued - Here's why.

Fair Value:US$87.0741.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
81 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28026.1% undervalued
185 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
71 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0